Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer(ADE-LACC) | not yet recruiting | Phase 2 | 35 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00365157 | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | active not recruiting | Phase 1 / Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02595892 | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | active not recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib(ROCSAN) | recruiting | Phase 2 / Phase 3 | 138 | ARCAGY/ GINECO GROUPOTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05287945 | Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 75 | Oncorena ABINDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT07226713 | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors(POSTPONE) | recruiting | Phase 2 | 32 | Medical College of WisconsinOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07256223 | A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) | recruiting | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07576335 | Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy(ROBOPREP) | recruiting | Phase 2 | 64 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer(ASpiRE) | recruiting | Phase 1 / Phase 2 | 78 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study(OHAI-NMIBC-01) | not yet recruiting | Phase 2 | 106 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07224009 | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | recruiting | Phase 2 | 60 | University of ArkansasOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE(SALVAGE) | not yet recruiting | Phase 2 | 62 | University of British ColumbiaOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT04597359 | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT06384222 | Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | active not recruiting | Phase 2 | 32 | Ivan de Kouchkovsky, MDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis(EXPLORE-RCC) | recruiting | Phase 2 | 69 | Qian QinOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07188896 | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) | recruiting | Phase 2 | 120 | Brian RiniOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 260 | Genentech, Inc.INDUSTRY | 3 | Sep 4, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01410942 | Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy | active not recruiting | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03173924 | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04633252 | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | active not recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06096870 | Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | recruiting | Phase 2 | 325 | CG Oncology, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 85 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07285694 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | active not recruiting | Phase 1 / Phase 2 | 190 | Arsenal Biosciences, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07578519 | Radiation Treatment of the Prostate That is Specially Adjusted for Each Person | recruiting | Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801664 | Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer | recruiting | Phase 2 | 90 | NYU Langone HealthOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03181867 | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | active not recruiting | Phase 2 | 360 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03762759 | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | active not recruiting | Phase 2 | 140 | Emory UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04917809 | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04997018 | A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer | active not recruiting | Phase 2 | 91 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial(PREDICT) | recruiting | Phase 2 | 474 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | not yet recruiting | Phase 2 | 44 | Guru SonpavdeOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials